<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958164</url>
  </required_header>
  <id_info>
    <org_study_id>135.323</org_study_id>
    <nct_id>NCT01958164</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion</brief_title>
  <official_title>A Multicenter, Open-label, Randomised, Clinical Trial to Compare the Efficacy and Safety of Actilyse 2 mg/ 2 ml Versus Saline Solution in Restoring Function of an Occluded Central Venous Access Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a multicentre, open-label, randomised, phase III study designed to evaluate the
      efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication</measure>
    <time_frame>120 minutes after first drug administration</time_frame>
    <description>Proportion (percentage) of patients with restored central venous access device (CVAD) function at 120 min after administration of the first dose of study medication (i.e. Actilyse® or saline solution).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restored CVAD Function 30 Minutes After Administration of Study Medication at Time 0</measure>
    <time_frame>30 minutes after first drug administration</time_frame>
    <description>Percentage of patients with restored CVAD function 30 minutes after administration of study medication at time 0 (i.e. Actilyse® or saline solution)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restored CVAD Function 30 Minutes After Administration of the Second Dose of Study Medication Actilyse</measure>
    <time_frame>150 minutes after first drug administration</time_frame>
    <description>Percentage of patients with restored CVAD function 30 minutes after administration of the second dose of study medication Actilyse (150 minutes after time 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restored CVAD Function 120 Minutes After Administration of the Second Dose of Study Medication Actilyse</measure>
    <time_frame>240 minutes after first drug administration</time_frame>
    <description>Percentage of patients with restored CVAD function 120 minutes after administration of the second dose of study medication Actilyse (240 minutes after time 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Restored CVAD Function After 1 Dose and 2 Doses, in Patients From the Actilyse Treatment Group.</measure>
    <time_frame>0 minutes and 240 minutes</time_frame>
    <description>This endpoint was defined as the number of doses required to achieve restored CVAD function in patients from the actilyse treatment group but was analysed as the percentage of participants who achieved restored CVAD function after 1 dose and 2 doses, in patients from the actilyse treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Catheter Obstruction</condition>
  <condition>Vascular Access Devices</condition>
  <arm_group>
    <arm_group_label>Actilyse 2 mg/2 ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution (NaCl 0.9%)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actilyse</intervention_name>
    <description>Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.</description>
    <arm_group_label>Saline solution (NaCl 0.9%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II</description>
    <arm_group_label>Saline solution (NaCl 0.9%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actilyse</intervention_name>
    <description>Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.</description>
    <arm_group_label>Actilyse 2 mg/2 ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actilyse</intervention_name>
    <description>Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.</description>
    <arm_group_label>Actilyse 2 mg/2 ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female patients between 18 and 80 years, who signed a written informed
             consent

          -  Patients with central venous access device occlusion, which occurred within 24-h
             before randomisation, where central venous access device is indicated for any of the
             following: fluid maintenance, chemotherapy, intravenous feeding, haemodialysis,
             long-term administration of antibiotics or other medication

          -  Patients with central venous access device occlusion occurred within 24-h before
             randomisation. Central venous access device is defined by inability to withdraw at
             least 3 ml of blood from the central venous access device. If multiple lumens are
             occluded, investigators are to choose and treat only one lumen for the study.

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with good clinical practice and the local legislation. Acceptable level of
             the following laboratory parameters:

               -  hemoglobin ≥ 80 g/L;

               -  total white blood cell count ≥ 2.0 x109/L;

               -  platelets ≥ 50.0 x109/L;

               -  fibrinogen ≥0.5 x lower limit of normal;

               -  international normalized ratio &lt;2 x upper limit of normal;

               -  activated partial thromboplastin time &lt;2 x upper limit of normal;

               -  total protein ≥ 35 g/l;

               -  alanine transaminase &lt;20 x upper limit of normal;

               -  aspartate transaminase &lt;20 x upper limit of normal;

               -  total bilirubin &lt;10 x upper limit of normal;

               -  creatinine &lt;6 x upper limit of normal;

               -  glucose &gt; 2.8 mmol/l.

        Exclusion criteria:

          -  Any clinical evidence of mechanical or non-thrombotic occlusion

          -  High risk for bleeding events

          -  High risk for embolic complications

          -  Any condition for which bleeding constitutes a significant hazard or would be
             particularly difficult to manage

          -  Administration of any fibrinolytic agent within 48 hours before start of study
             treatment

          -  Patients who have had any of the following within the previous 48 hours before start
             of study treatment:

               -  surgery

               -  obstetrical delivery

               -  percutaneous biopsy of viscera or deep tissues

               -  puncture of non-compressible vessels

               -  active internal bleeding

          -  Patients who have thrombocytopenia, other hemostatic defects (including those
             secondary to severe hepatic or renal disease).

          -  Pregnancy and lactation.

          -  Previously known positive results from infectious serology for Human Immunodeficiency
             Virus (HIV) or hepatitis B surface antigen (HBsAg), or hepatitis C virus.

          -  Known hypersensitivity to alteplase or gentamicin, or any excipient of Actilyse - Body
             weight &lt;30 kg.

          -  Administration of any fibrinolytic agent within 48 hours before start of study
             treatment.

          -  Participation in another investigational trial within 30 days prior to the Screening
             Visit.

          -  Concomitant treatment with angiotensin-converting-enzyme inhibitors.

          -  Impossibility to infuse fluids at the volume necessary to infuse study drug (2 ml)
             into the central venous access device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>135.323.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>135.323.2 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>135.323.3 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>135.323.5 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>135.323.7 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <results_first_submitted>April 16, 2015</results_first_submitted>
  <results_first_submitted_qc>April 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2015</results_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Actilyse</title>
          <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
        </group>
        <group group_id="P2">
          <title>Saline Solution + Actilyse</title>
          <description>Patients received one dose of saline solution (NaCl 0.9% - 2ml), administered intravenously, at time 0. A first dose of Actilyse 2mg/2ml was administered intravenously to patients at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">Randomised and treated</participants>
                <participants group_id="P2" count="10">Randomised and treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomised patients</population>
      <group_list>
        <group group_id="B1">
          <title>Actilyse</title>
          <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
        </group>
        <group group_id="B2">
          <title>Saline Solution + Actilyse</title>
          <description>Patients received one dose of saline solution (NaCl 0.9% - 2ml), administered intravenously, at time 0. A first dose of Actilyse 2mg/2ml was administered intravenously to patients at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" lower_limit="26" upper_limit="74"/>
                    <measurement group_id="B2" value="63.9" lower_limit="35" upper_limit="76"/>
                    <measurement group_id="B3" value="60.9" lower_limit="26" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication</title>
        <description>Proportion (percentage) of patients with restored central venous access device (CVAD) function at 120 min after administration of the first dose of study medication (i.e. Actilyse® or saline solution).</description>
        <time_frame>120 minutes after first drug administration</time_frame>
        <population>Full analysis set (FAS) which included all randomised patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Actilyse</title>
            <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution + Actilyse</title>
            <description>Patients received one dose of saline solution (NaCl 0.9% - 2ml), administered intravenously, at time 0. A first dose of Actilyse 2mg/2ml was administered intravenously to patients at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication</title>
          <description>Proportion (percentage) of patients with restored central venous access device (CVAD) function at 120 min after administration of the first dose of study medication (i.e. Actilyse® or saline solution).</description>
          <population>Full analysis set (FAS) which included all randomised patients who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="35.8" upper_limit="99.6"/>
                    <measurement group_id="O2" value="10.0" lower_limit="0.2" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>73.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.3</ci_lower_limit>
            <ci_upper_limit>89.3</ci_upper_limit>
            <estimate_desc>Difference calculated as actilyse minus saline solution</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restored CVAD Function 30 Minutes After Administration of Study Medication at Time 0</title>
        <description>Percentage of patients with restored CVAD function 30 minutes after administration of study medication at time 0 (i.e. Actilyse® or saline solution)</description>
        <time_frame>30 minutes after first drug administration</time_frame>
        <population>Full analysis set (FAS) which included all randomised patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Actilyse</title>
            <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution + Actilyse</title>
            <description>Patients received one dose of saline solution (NaCl 0.9% - 2ml), administered intravenously, at time 0. A first dose of Actilyse 2mg/2ml was administered intravenously to patients at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Restored CVAD Function 30 Minutes After Administration of Study Medication at Time 0</title>
          <description>Percentage of patients with restored CVAD function 30 minutes after administration of study medication at time 0 (i.e. Actilyse® or saline solution)</description>
          <population>Full analysis set (FAS) which included all randomised patients who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>66.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.7</ci_lower_limit>
            <ci_upper_limit>90.3</ci_upper_limit>
            <estimate_desc>Difference calculated as actilyse minus saline solution</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restored CVAD Function 30 Minutes After Administration of the Second Dose of Study Medication Actilyse</title>
        <description>Percentage of patients with restored CVAD function 30 minutes after administration of the second dose of study medication Actilyse (150 minutes after time 0)</description>
        <time_frame>150 minutes after first drug administration</time_frame>
        <population>All patients in the FAS who did not have restored CVAD function 120 minutes after first drug administration</population>
        <group_list>
          <group group_id="O1">
            <title>Actilyse</title>
            <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution + Actilyse</title>
            <description>Patients received one dose of saline solution (NaCl 0.9% - 2ml), administered intravenously, at time 0. A first dose of Actilyse 2mg/2ml was administered intravenously to patients at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Restored CVAD Function 30 Minutes After Administration of the Second Dose of Study Medication Actilyse</title>
          <description>Percentage of patients with restored CVAD function 30 minutes after administration of the second dose of study medication Actilyse (150 minutes after time 0)</description>
          <population>All patients in the FAS who did not have restored CVAD function 120 minutes after first drug administration</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="55.6" lower_limit="21.2" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restored CVAD Function 120 Minutes After Administration of the Second Dose of Study Medication Actilyse</title>
        <description>Percentage of patients with restored CVAD function 120 minutes after administration of the second dose of study medication Actilyse (240 minutes after time 0)</description>
        <time_frame>240 minutes after first drug administration</time_frame>
        <population>All patients in the FAS who did not have restored CVAD function 120 minutes after first drug administration</population>
        <group_list>
          <group group_id="O1">
            <title>Actilyse</title>
            <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution + Actilyse</title>
            <description>Patients received one dose of saline solution (NaCl 0.9% - 2ml), administered intravenously, at time 0. A first dose of Actilyse 2mg/2ml was administered intravenously to patients at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Restored CVAD Function 120 Minutes After Administration of the Second Dose of Study Medication Actilyse</title>
          <description>Percentage of patients with restored CVAD function 120 minutes after administration of the second dose of study medication Actilyse (240 minutes after time 0)</description>
          <population>All patients in the FAS who did not have restored CVAD function 120 minutes after first drug administration</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="77.8" lower_limit="39.9" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Restored CVAD Function After 1 Dose and 2 Doses, in Patients From the Actilyse Treatment Group.</title>
        <description>This endpoint was defined as the number of doses required to achieve restored CVAD function in patients from the actilyse treatment group but was analysed as the percentage of participants who achieved restored CVAD function after 1 dose and 2 doses, in patients from the actilyse treatment group.</description>
        <time_frame>0 minutes and 240 minutes</time_frame>
        <population>All patients in the FAS who were randomised to the Actilyse treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Actilyse</title>
            <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Restored CVAD Function After 1 Dose and 2 Doses, in Patients From the Actilyse Treatment Group.</title>
          <description>This endpoint was defined as the number of doses required to achieve restored CVAD function in patients from the actilyse treatment group but was analysed as the percentage of participants who achieved restored CVAD function after 1 dose and 2 doses, in patients from the actilyse treatment group.</description>
          <population>All patients in the FAS who were randomised to the Actilyse treatment group</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After 1 dose of Actilyse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 2 doses of Actilyse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until the end of that day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Actilyse</title>
          <description>Patients received one dose of Actilyse 2mg/2ml, administered intravenously, at time 0. A second dose was administered at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
        </group>
        <group group_id="E2">
          <title>Saline Solution + Actilyse</title>
          <description>Patients received one dose of saline solution (NaCl 0.9% - 2ml), administered intravenously, at time 0. A first dose of Actilyse 2mg/2ml was administered intravenously to patients at 120 minutes if central venous access device (CVAD) function had not been restored.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was stopped prematurely due to slow recruitment of patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

